fda semaglutide compounding news proposes a new GLP-1 crackdown FDA issues warning about some

ICP was recorded with the MPR-1 monitor (Raumedic) in a standardized supine position as previously described

Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: A systematic review and meta-analysis of randomized controlled trials

Weeks three and four solidify the adaptation

The El Paso investigators said they initiated their research to move beyond smaller studies because the real-world impact of GLP-1 RA on multiple co-occurrence of SUD (substance use disorder) has not been systematically investigated. To address this gap, the team conducted a retrospective nested case-control study using data from the NIHs All of Us Research Program